| __timestamp | Opthea Limited | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2652041 | 7751000 |
| Thursday, January 1, 2015 | 2361587 | 10251000 |
| Friday, January 1, 2016 | 4472869 | 9575000 |
| Sunday, January 1, 2017 | 5030957 | 10912000 |
| Monday, January 1, 2018 | 4988941 | 11049000 |
| Tuesday, January 1, 2019 | 5196412 | 11646000 |
| Wednesday, January 1, 2020 | 6652774 | 13265000 |
| Friday, January 1, 2021 | 18418247 | 25805000 |
| Saturday, January 1, 2022 | 24827066 | 35182000 |
| Sunday, January 1, 2023 | 41896408 | 94999000 |
| Monday, January 1, 2024 | 15488619 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for operational efficiency. Opthea Limited and Viridian Therapeutics, Inc. have shown distinct trends in their SG&A expenses over the past decade. From 2014 to 2023, Opthea's SG&A expenses grew by approximately 1,480%, peaking in 2023. In contrast, Viridian's expenses surged by about 1,125% during the same period, with a notable spike in 2023. This suggests a strategic shift or expansion in operations for both companies. However, data for 2024 is incomplete, highlighting the need for cautious interpretation. Understanding these trends can provide insights into each company's strategic priorities and financial health. Investors and stakeholders should consider these dynamics when evaluating potential growth and investment opportunities in the biotech sector.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Opthea Limited
Comparing SG&A Expenses: Sanofi vs Opthea Limited Trends and Insights
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Viridian Therapeutics, Inc.
Genmab A/S and Opthea Limited: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Pharming Group N.V. and Opthea Limited
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Opthea Limited vs Alpine Immune Sciences, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Opthea Limited and Mesoblast Limited
Comparing SG&A Expenses: Alpine Immune Sciences, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Veracyte, Inc. vs Viridian Therapeutics, Inc.